Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFA Combined with CIK Cells for Colorectal Cancer Liver Metastases
NCT02419677Phase 3Completed
- Sponsor
- Changzhou First People's Hospital
- Start
- Jan 2010
- Primary completion
- Dec 2014
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 3 trial of unmodified CIK in Colorectal cancer with liver metastases (CRLM), sponsored by Changzhou First People's Hospital. Started Jan 2010; status: completed.
02
Drugs
unmodified CIK
03
Conditions
Colorectal cancer with liver metastases (CRLM)
Beyond the preview
Go deeper on NCT02419677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419677.